Tuesday, August 18, 2026
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 24, 2026

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

View original at globenewswire.com
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • OCU410 medium dose group showed 27% slower rate of ellipsoid zone (EZ) loss compared to control, indicating structural preservation of photoreceptors

    60% confidence
  • Phase 2 data consistently demonstrates statistically significant reduction of GA lesion growth after treatment with OCU410 optimal dose, benchmarked against natural history data

    60% confidence
  • OCU410 moves Ocugen one step closer to bringing a transformative one-time treatment to GA patients globally

    60% confidence
  • Anticipated Phase 3 pivotal confirmatory trial will include up to 300 subjects with adaptive design powered at over 95%

    60% confidence
  • No serious adverse events and no adverse events of special interest related to OCU410 reported to date

    60% confidence
  • Subgroup analysis showed 33% reduction in lesion growth compared to control in medium dose OCU410 for subjects with baseline GA lesions ≥5 mm2 and ≤17.5 mm2

    60% confidence
  • Current GA therapies require 6-12 injections per year indefinitely, leading to substantial burden and significant dropout rates in real-world practice

    60% confidence
  • OCU410 shows potential 2X treatment benefit compared to currently approved therapies which report 15% and 22% reductions at 12 and 24 months respectively

    60% confidence
  • No OCU410-related serious adverse events observed and no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy reported to date

    60% confidence
  • OCU410 has the potential to eliminate chronic treatment burden associated with monthly or every-other-month intravitreal injections and reduce treatment attrition

    60% confidence
  • Phase 2 trial confirmed robust treatment effect from a well-controlled trial, enabling Phase 3 progression with high confidence

    60% confidence
  • Optimal dose (medium) of OCU410 demonstrates statistically significant 31% reduction in lesion growth versus control at 12 months (p<0.05)

    60% confidence
  • 55% of treated patients demonstrated ≥30% lesion size reduction versus control

    60% confidence

Cited in these Via News reports